IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10421718 B1

PDFFull Text
Date of Patent:
Sep. 24, 2019

Filed:

Nov. 16, 2017

Ebna1 inhibitors and their method of use

Applicant:

The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US);

Inventors:

Troy E. Messick, Upper Darby, PA (US);

Garry R. Smith, Royersford, PA (US);

Allen B. Reitz, Lansdale, PA (US);

Paul M. Lieberman, Wynnewood, PA (US);

Mark E. McDonnell, Lansdale, PA (US);

Yan Zhang, Fort Washington, PA (US);

Venkata Velvadapu, Ankeny, IA (US);

Assignee:

THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Philadelphia, PA (US);

Attorneys:

Saul Ewing Arnstein & Lehr LLP

Domingos J. Silva

Primary Examiner:

Shengjun Wang

Int. Cl.
CPC ...
A61K 31/195 (2006.01); A61K 31/405 (2006.01); A61K 31/41 (2006.01); A61K 31/42 (2006.01); A61K 31/415 (2006.01); A61K 31/40 (2006.01); C07D 207/327 (2006.01); A61K 31/404 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/192 (2006.01); A61K 31/44 (2006.01); C07C 229/56 (2006.01); C07C 255/54 (2006.01); C07C 255/55 (2006.01); C07C 211/27 (2006.01); C07C 217/84 (2006.01); C07C 233/11 (2006.01); C07C 233/64 (2006.01); C07C 233/65 (2006.01); C07C 235/58 (2006.01); C07C 311/08 (2006.01); C07C 311/16 (2006.01); C07C 311/17 (2006.01); C07C 317/14 (2006.01); C07D 235/06 (2006.01); C07D 403/10 (2006.01); C07D 239/26 (2006.01); C07D 409/10 (2006.01); C07D 417/10 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 209/08 (2006.01); C07D 295/155 (2006.01); C07D 213/55 (2006.01); C07C 53/18 (2006.01); C07C 63/66 (2006.01); C07C 65/19 (2006.01); C07C 65/28 (2006.01); C07C 229/64 (2006.01); C07C 317/44 (2006.01); C07D 207/08 (2006.01); C07D 207/12 (2006.01); C07D 207/14 (2006.01); C07D 207/16 (2006.01); C07D 211/70 (2006.01); C07D 213/64 (2006.01); C07D 213/74 (2006.01); C07D 215/14 (2006.01); C07D 231/12 (2006.01); C07D 249/06 (2006.01); C07D 277/30 (2006.01); C07D 307/79 (2006.01); C07D 333/54 (2006.01); C07D 401/04 (2006.01); C07D 401/10 (2006.01);
U.S. Cl.
CPC ...
C07D 207/327 (2013.01); A61K 31/192 (2013.01); A61K 31/404 (2013.01); A61K 31/44 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); C07C 53/18 (2013.01); C07C 63/66 (2013.01); C07C 65/19 (2013.01); C07C 65/28 (2013.01); C07C 211/27 (2013.01); C07C 217/84 (2013.01); C07C 229/56 (2013.01); C07C 229/64 (2013.01); C07C 233/11 (2013.01); C07C 233/64 (2013.01); C07C 233/65 (2013.01); C07C 235/58 (2013.01); C07C 255/54 (2013.01); C07C 255/55 (2013.01); C07C 311/08 (2013.01); C07C 311/16 (2013.01); C07C 311/17 (2013.01); C07C 317/14 (2013.01); C07C 317/44 (2013.01); C07D 207/08 (2013.01); C07D 207/12 (2013.01); C07D 207/14 (2013.01); C07D 207/16 (2013.01); C07D 209/08 (2013.01); C07D 211/70 (2013.01); C07D 213/55 (2013.01); C07D 213/64 (2013.01); C07D 213/74 (2013.01); C07D 215/14 (2013.01); C07D 231/12 (2013.01); C07D 235/06 (2013.01); C07D 239/26 (2013.01); C07D 249/06 (2013.01); C07D 277/30 (2013.01); C07D 295/155 (2013.01); C07D 307/79 (2013.01); C07D 333/54 (2013.01); C07D 401/04 (2013.01); C07D 401/10 (2013.01); C07D 403/10 (2013.01); C07D 409/10 (2013.01); C07D 417/10 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07C 2601/02 (2017.05);
Abstract

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

Find Patent Forward Citations

Loading…